Results 51 to 60 of about 854 (146)

Lasmiditan: First Approval

, 2019
Compliance with Ethical StandardsFunding: The preparation of this review was not supported by any external funding.Conflict of interest: During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on ...
Yvette Lamb (6930427)
core   +1 more source

Comparison of the adverse events of preprandial and postprandial lasmiditan intake: A retrospective chart review

Cephalalgia Reports
Background Lasmiditan is suitable for the acute treatment of migraine in patients who are intolerant or unresponsive to triptans. However, lasmiditan can cause adverse events that affect treatment adherence. The effects of predose food consumption on the
Yuu Tatsuoka, Tamae Naruse, Atsushi Shima, Ryosuke Takahashi, Yoshihisa Tatsuoka   +4 more
doaj   +1 more source

Development of a machine learning (ML) model to predict 3‐month response to CGRP monoclonal antibodies in migraine: A pilot evaluation of physician‐ML model interaction

Headache: The Journal of Head and Face Pain, EarlyView.
Plain Language Summary Monoclonal antibodies that target calcitonin gene‐related peptide (CGRP‐mAbs) are effective treatments for preventing migraine in many patients but are expensive, and physicians cannot easily predict which patients will benefit from them.
Masahito Katsuki, Muneto Tatsumoto, Tomokazu Shimazu, Yasuhiko Matsumori, Marina Romozzi, Omid Kohandel Gargari, Alicia Gonzalez‐Martinez, Woo‐Seok Ha, Yutaro Fuse, Shiho Suzuki, Saro Kobayashi, Tomohiko Shiina, Mukuto Shioda, Hiroaki Fujita, Koichi Hirata, Yuya Kano, Ryosuke Fukazawa, Jackson T. S. Cheung, Siobhán O'Connor, Tomás Ward, Kieran Moran, Keisuke Suzuki   +21 more
wiley   +1 more source

Real‐world diagnosis and treatment of individuals with migraine in the United States: The Migraine Insights in Diagnosis and Treatment (MIND) study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective The objective of this study was to describe the real‐world diagnosis and treatment patterns of individuals newly diagnosed with migraine in the United States (US). Background Over 10% of adults in the US are living with migraine.
Fred Cohen, Vincent Martin, Avani Patel, Shelby L. Corman, Katie B. Tellor, Meghan Fajardo, D. Cortney Hayflinger, Simon Dagenais   +7 more
wiley   +1 more source

Efficacy and safety of Lasmiditan for acute treatment of migraine in adults: A meta-analysis

, 2020
The present meta-analysis has been planned to evaluate the efficacy and safety of Lasmiditan for acute treatment of migraine in ...
RITUPARNA MAITI
core   +1 more source

The ditans, a new class for acute migraine: Minireview

Journal of Current Research in Scientific Medicine, 2020
Lasmiditan (LDT), a new drug, was approved by the Food and Drug Administration in October 2019 for acute migraines with or without aura. LDT belongs to a new class of drugs “-ditans,” in which the mechanism is different from the triptans since it does ...
Jamir Pitton Rissardo, Ana Letícia Fornari Caprara   +1 more
doaj   +1 more source

Could calcitonin gene‐related peptide inhibitors prevent status epilepticus?

Epilepsia, Volume 67, Issue 10, Page e198-e201, October 2026.
Abstract Calcitonin gene‐related peptide (CGRP) inhibitors modulate pain and neuroinflammation, a recognized contributor to epileptogenesis and status epilepticus (SE). We examined the association between CGRP inhibitor use and SE hospitalization in epilepsy patients with comorbid migraine.
Michael Nsaka, Noor Baban, Sepideh Allahdadian, Armin Scheffler, Diana Lindner, Dagny Holle, Alain Lekoubou   +6 more
wiley   +1 more source

5-HT1F Receptor Agonist Ameliorates Mechanical Allodynia in Neuropathic Pain via Induction of Mitochondrial Biogenesis and Suppression of Neuroinflammation

Frontiers in Pharmacology, 2022
Neuropathic pain is a devastating disease that affects millions of people worldwide. Serotonin (5-hydroxytryptamine, 5-HT) is involved in pain modulation.
Long-Qing Zhang, Ya-Qun Zhou, Jia-Yan Li, Jia Sun, Shuang Zhang, Jia-Yi Wu, Shao-Jie Gao, Xue-Bi Tian, Wei Mei   +8 more
doaj   +1 more source

2‐Chloro‐5‐(trifluoromethyl)aniline‐Derived Schiff Base Palladium(II) Complexes: From Molecular Design to Acute Toxicity Assessment

ChemistryOpen, Volume 15, Issue 10, October 2026.
Four new Schiff bases derived from 2‐chloro‐5‐(trifluoromethyl)aniline and their corresponding palladium(II) complexes were obtained and analyzed by multiple spectroscopic techniques. Single‐crystal X‐ray diffraction elucidated the structures of all the ligands and complexes 2 and 4. Their toxicity was assessed on Triticum aestivum L.
Andreea Elena Ştefan, Cristina Elena Dinu‐Pîrvu, Sergiu Shova, Ştefania Felicia Bărbuceanu, Teodora Venera Apostol, Diana Carolina Ilieş, Mihaela Badea, Mihaela Dinu, Robert Viorel Ancuceanu, Doina Drăgănescu, Elena Pahonţu   +10 more
wiley   +1 more source

Personalized machine learning prediction of next‐day migraine persistence using digital headache diary data

Headache: The Journal of Head and Face Pain, Volume 66, Issue 9, Page 2066-2077, October 2026.
Abstract Objectives/Background Migraine is a disabling neurological disorder with substantial interindividual variability. Predicting whether an ongoing migraine attack will persist into the following day remains challenging. We evaluated the feasibility and predictive performance of personalized machine learning models for predicting next‐day migraine
Ya‐Hsiu Tsai, Chen‐Lin Chiou, Jun‐Jun Lee, Chun‐Ming Yang, Kao‐Chang Lin, Tain‐Junn Cheng, Ja‐Hwung Su, Cheng‐Hsin Chuang   +7 more
wiley   +1 more source